Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Research & Development (2016 - 2025)

Historic Research & Development for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to -$3.2 billion.

  • Novartis Ag's Research & Development fell 1129.49% to -$3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$11.2 billion, marking a year-over-year decrease of 1175.41%. This contributed to the annual value of -$11.2 billion for FY2025, which is 1175.41% down from last year.
  • According to the latest figures from Q4 2025, Novartis Ag's Research & Development is -$3.2 billion, which was down 1129.49% from -$2.9 billion recorded in Q3 2025.
  • Novartis Ag's Research & Development's 5-year high stood at -$2.2 billion during Q4 2022, with a 5-year trough of -$3.9 billion in Q3 2023.
  • Over the past 5 years, Novartis Ag's median Research & Development value was -$2.4 billion (recorded in 2021), while the average stood at -$2.6 billion.
  • In the last 5 years, Novartis Ag's Research & Development plummeted by 5440.6% in 2023 and then skyrocketed by 3905.73% in 2024.
  • Over the past 5 years, Novartis Ag's Research & Development (Quarter) stood at -$2.4 billion in 2021, then increased by 8.01% to -$2.2 billion in 2022, then dropped by 15.84% to -$2.6 billion in 2023, then decreased by 10.71% to -$2.8 billion in 2024, then fell by 11.29% to -$3.2 billion in 2025.
  • Its Research & Development stands at -$3.2 billion for Q4 2025, versus -$2.9 billion for Q3 2025 and -$2.7 billion for Q2 2025.